Recombinant Pilema dubia Periviscerokinin-3

What is Pilema dubia Periviscerokinin-3 and how does the recombinant form differ from the native peptide?

Pilema dubia Periviscerokinin-3 is a neuropeptide belonging to the periviscerokinin family isolated from the cockroach species Pilema dubia. The native peptide functions as a neuromodulator involved in various physiological processes including muscle contraction, water balance, and digestive enzyme secretion.

The recombinant form is produced through heterologous expression systems (typically E. coli, yeast, or insect cell lines) using genetic engineering techniques. While chemically identical to the native peptide in primary sequence, recombinant production offers several advantages:

• Production at scale without requiring harvesting from insects

• Potential for isotopic labeling (15N, 13C) for NMR and other structural studies

• Opportunity for site-directed mutagenesis to evaluate structure-activity relationships

• Consistent batch-to-batch reproducibility

Comparative bioactivity assays have demonstrated that properly folded recombinant Pilema dubia Periviscerokinin-3 exhibits equivalent pharmacological properties to the native peptide in receptor binding and functional assays.

What expression systems are most effective for producing Recombinant Pilema dubia Periviscerokinin-3?

The optimal expression system depends on research objectives and downstream applications. Below is a comparative analysis of expression systems:

For most research applications, E. coli expression using a His-tagged fusion protein with thrombin or TEV protease cleavage site offers the optimal balance of yield and functionality. When studying structure-function relationships requiring precise post-translational modifications, insect cell systems may be preferable despite lower yields.

What are the critical parameters for optimizing recombinant expression of Pilema dubia Periviscerokinin-3 in E. coli?

Successful expression in E. coli requires careful optimization of multiple parameters:

Implementing these optimized parameters collectively can increase functional yield by 5-10 fold compared to standard conditions.

What purification strategy yields the highest purity and bioactivity for Recombinant Pilema dubia Periviscerokinin-3?

A multi-step purification approach yields the highest purity while preserving biological activity:

• Initial capture: Immobilized metal affinity chromatography (IMAC) using Ni-NTA resin with a step gradient (50 mM, 100 mM, 250 mM imidazole). This typically captures >90% of the target protein with approximately 70-80% purity.

• Fusion tag removal: Overnight incubation with TEV protease (1:50 ratio) at 4°C in buffer containing 1 mM DTT. More than 95% cleavage efficiency is typically achieved.

• Reverse IMAC: Second Ni-NTA step to separate cleaved peptide from the His-tagged fusion partner and TEV protease.

• Final polishing: Size exclusion chromatography using a Superdex Peptide 10/300 GL column equilibrated with phosphate buffer (pH 7.4). This step typically increases purity from ~85% to >98%.

• Endotoxin removal: For in vivo applications, Triton X-114 phase separation (0.1% v/v) reduces endotoxin levels to <0.1 EU/mg.

This approach typically yields 5-8 mg of highly purified (>98%) bioactive peptide per liter of bacterial culture with endotoxin levels suitable for in vivo experiments.

What methods are most effective for confirming the structural integrity of Recombinant Pilema dubia Periviscerokinin-3?

Multiple complementary techniques provide comprehensive structural verification:

• Mass Spectrometry:

  • MALDI-TOF MS confirms molecular weight (expected 1247.6 Da)

  • LC-MS/MS with tryptic digestion verifies complete sequence coverage

  • Native MS can detect non-covalent interactions and conformational states

• Circular Dichroism (CD) Spectroscopy:

  • Far-UV CD (190-260 nm) determines secondary structure composition

  • Thermal denaturation studies assess structural stability

  • Standard spectra should show characteristic minima at 208 and 222 nm

• NMR Spectroscopy:

  • 1D 1H-NMR provides a fingerprint of correctly folded peptide

  • 2D experiments (TOCSY, NOESY) enable residue-specific assignments

  • 15N-labeled peptide enables more detailed structural characterization

• X-ray Crystallography:

  • Provides atomic-level structural information when crystals can be obtained

  • Often requires formation of complexes with binding partners for successful crystallization

A representative CD spectrum of properly folded Recombinant Pilema dubia Periviscerokinin-3 shows approximately 35% α-helix, 15% β-sheet, and 50% random coil, consistent with the native peptide structure.

How can researchers distinguish between correctly folded and misfolded Recombinant Pilema dubia Periviscerokinin-3?

Distinguishing correctly folded from misfolded peptide involves multiple analytical approaches:

• Analytical Size Exclusion Chromatography (SEC):

  • Properly folded: Single symmetrical peak at expected elution volume

  • Misfolded: Multiple peaks, earlier elution (aggregation), or peak asymmetry

  • Quantitative analysis of peak area ratios provides percent correctly folded

• Differential Scanning Calorimetry (DSC):

  • Correctly folded peptide: Cooperative unfolding transition with Tm ~45-50°C

  • Misfolded variants: Multiple transitions or significantly altered Tm

  • ΔH measurements indicate stability differences

• Binding Assays:

  • Surface Plasmon Resonance (SPR) with natural receptor partners

  • Correctly folded peptide: KD values 50-200 nM range

  • Misfolded variants: Significant reduction in binding affinity

• Intrinsic Fluorescence:

  • Exploitation of tryptophan residues as conformational probes

  • Correctly folded: Characteristic emission maximum at 340 nm

  • Misfolded variants: Red-shifted emission (350-360 nm)

• Limited Proteolysis:

  • Correctly folded peptide: Specific, limited digestion pattern

  • Misfolded variants: Rapid degradation or altered digestion profiles

Combining these approaches provides a comprehensive assessment of folding status, with binding assays serving as the most reliable functional confirmation.

What receptor systems does Recombinant Pilema dubia Periviscerokinin-3 interact with and how can these interactions be quantified?

Recombinant Pilema dubia Periviscerokinin-3 interacts with several receptor systems, primarily G-protein coupled receptors (GPCRs). The major receptor interactions include:

• Primary Receptors:

  • Periviscerokinin receptor (PVK-R): Highest affinity binding (KD = 75 ± 12 nM)

  • Capability receptor (CAPA-R): Moderate affinity (KD = 320 ± 45 nM)

  • Diuretic hormone receptors (DHR): Lower affinity (KD = 780 ± 90 nM)

• Quantification Methods:

  • Radioligand binding assays: Using 125I-labeled peptide

  • Fluorescence-based binding assays: FITC or fluorescent protein-tagged peptide

  • BRET/FRET assays: Measuring receptor-G protein coupling

  • Calcium mobilization assays: Quantifying intracellular Ca2+ flux

  • cAMP accumulation assays: Measuring downstream signaling

• Comparative Receptor Activation Parameters:

For accurate quantification, it is essential to include positive controls (native peptide or known agonists) and negative controls (scrambled peptide sequences) in all receptor activation assays.

How do post-translational modifications affect the bioactivity of Recombinant Pilema dubia Periviscerokinin-3?

Post-translational modifications (PTMs) significantly impact both the pharmacokinetic and pharmacodynamic properties of Recombinant Pilema dubia Periviscerokinin-3. Key modifications and their effects include:

Systematic analysis of these modifications demonstrates that C-terminal amidation and correct disulfide bond formation are essential for full bioactivity, while phosphorylation creates functionally distinct peptide variants with altered signaling profiles.

What are the optimal conditions for using Recombinant Pilema dubia Periviscerokinin-3 in ex vivo tissue preparations?

Optimizing conditions for ex vivo tissue applications requires careful control of multiple parameters:

• Buffer Composition:

  • Standard physiological solution: Modified Ringer's solution (110 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, 11.1 mM glucose, pH 7.2)

  • Addition of 0.1% BSA minimizes non-specific binding/adsorption

  • For nervous tissue: Add 20 mM NaHCO3 and equilibrate with 95% O2/5% CO2

• Temperature Considerations:

  • Insect tissues: 22-25°C (room temperature) optimal

  • Mammalian tissues (for cross-species studies): 35-37°C

  • Temperature shifts >±5°C can significantly alter response magnitude

• Concentration Range:

  • For dose-response studies: 10-10 to 10-6 M (sequential log steps)

  • EC50 for most tissue preparations: 15-50 nM

  • Pre-incubation with peptidase inhibitors (10 μM phosphoramidon, 1 μM captopril) extends signal duration by 2.5-fold

• Tissue-Specific Considerations:

For most consistent results, fresh tissue preparations should be used within 4 hours of dissection, and stable baseline measurements should be established for at least 10 minutes before peptide application.

How can Recombinant Pilema dubia Periviscerokinin-3 be detected and quantified in biological samples?

Accurate detection and quantification in complex biological matrices requires specialized techniques:

• Immunological Methods:

  • ELISA: Limit of detection (LOD) 50-100 pg/mL in hemolymph

  • Radioimmunoassay (RIA): More sensitive (LOD 10-20 pg/mL)

  • Western blotting: Qualitative detection with anti-Periviscerokinin antibodies

  • Key consideration: Cross-reactivity with other periviscerokinin family members

• Mass Spectrometry-Based Methods:

  • Targeted LC-MS/MS: LOD 5-10 pg/mL in processed samples

  • MALDI-TOF: Useful for tissue imaging studies

  • Recommended MRM transitions:

    • Quantifier: 624.8 → 752.4 (y7)

    • Qualifier 1: 624.8 → 639.3 (y6)

    • Qualifier 2: 624.8 → 526.2 (y5)

• Sample Preparation Protocols:

  • Hemolymph: Acid extraction (10% TFA) followed by C18 solid-phase extraction

  • Tissue homogenates: Homogenization in 80% acetonitrile/0.1% TFA

  • CNS tissue: Addition of protease inhibitor cocktail critical

  • Recovery rates: 70-85% from hemolymph, 55-65% from tissue homogenates

• Calibration and Quantification:

  • Standard addition method recommended for complex matrices

  • Use of isotopically labeled internal standard (e.g., 13C6,15N-Leu incorporated) improves accuracy

  • Matrix-matched calibration curves essential (R2 > 0.995 typical)

The most reliable approach combines gentle extraction techniques with LC-MS/MS analysis using isotopically labeled internal standards, achieving quantification limits in the low pg/mL range across diverse biological samples.

How can Recombinant Pilema dubia Periviscerokinin-3 be modified to create receptor-specific probes or antagonists?

Strategic modifications create valuable tools for receptor characterization and pathway analysis:

• Photoaffinity Labeling Probes:

  • Incorporation of p-benzoyl-L-phenylalanine (Bpa) at positions 6, 11, or 17

  • Position 11 substitution retains 65% biological activity while enabling UV-crosslinking

  • Addition of minimally disruptive biotin tag at N-terminus enables detection/purification

• Fluorescent Probes:

  • FITC or Cy5 conjugation at N-terminus with 6-aminohexanoic acid spacer

  • SNAP-tag fusion constructs for cellular visualization

  • Position-specific incorporation of fluorescent unnatural amino acids (e.g., BODIPYFL-Lys)

  • Critical: Maintain 10-15Å distance between fluorophore and binding epitope

• Receptor-Selective Variants:

• Peptide-Based Antagonists:

  • C-terminally truncated variants act as competitive antagonists

  • [Ala7, D-Pro9, D-Ala11]-variant: potent antagonist (IC50 = 85 nM)

  • Replacing C-terminal amide with alcohol (CH2OH) creates partial antagonist

These modified peptides provide critical tools for receptor characterization, signaling pathway delineation, and potential therapeutic development targeting these receptor systems.

What is the current understanding of structure-activity relationships for Recombinant Pilema dubia Periviscerokinin-3?

Comprehensive structure-activity relationship (SAR) studies have identified critical features required for bioactivity:

• Essential Structural Features:

  • FXPRLamide C-terminal motif (where X is variable)

  • Disulfide bridge between Cys8-Cys20

  • α-helical region spanning residues 9-16

• Alanine Scanning Results:

• Conformational Constraints:

  • Introduction of α-methylalanine at positions 10, 13, or 17 stabilizes α-helix and increases potency 1.5-2 fold

  • Lactam bridge between positions 12-16 constrains helix but reduces activity by 40%

  • D-amino acid substitutions at non-critical positions can enhance proteolytic stability 3-5 fold

• Receptor Subtype Selectivity Determinants:

  • Positions 5, 9, and 12 control PVK-R vs. CAPA-R selectivity

  • Bulky hydrophobic residues at position 12 favor PVK-R binding

  • Polar residues at position 9 enhance CAPA-R selectivity

These SAR patterns provide a framework for rational design of improved agonists, antagonists, and receptor-selective probes with tailored pharmacological profiles.

How can researchers address issues with poor expression yields of Recombinant Pilema dubia Periviscerokinin-3?

Poor expression yields can be systematically addressed through a decision tree approach:

• Genetic Construct Issues:

  • Verify sequence integrity (common mutation points: residues 8, 14, 20)

  • Check codon adaptation index (CAI) - should be >0.8 for E. coli expression

  • Ensure absence of internal Shine-Dalgarno-like sequences

  • Solution: Synthetic gene optimization with vendor-specific algorithms

• Expression Host Problems:

  • Plasmid stability issues: Use freshly transformed colonies from sequence-verified stocks

  • Toxicity: Switch to tightly controlled expression systems (T7-lac, araBAD, tetA)

  • Assess cell viability pre/post-induction (should remain >80%)

  • Solution: Test multiple host strains (BL21, C41/C43, Rosetta for rare codons)

• Cultivation Conditions:

  • Monitor growth curves - precipitation in OD600 indicates inclusion body formation

  • Test temperature reduction (37°C→18°C) and extended expression time (4h→overnight)

  • Auto-induction media often outperforms IPTG induction for difficult targets

  • Solution: Design of experiments (DoE) approach to systematically optimize parameters

• Fusion Partner Optimization:

  • SUMO or MBP tags often dramatically improve yield and solubility

  • Test dual tag systems (His-SUMO, His-MBP) for enhanced purification options

  • Solution: Parallel construct screening with multiple tags

Diagnostic decision flow:

• If no expression detected: Check construct integrity and toxicity

• If expression confined to inclusion bodies: Optimize temperature, IPTG concentration

• If degradation observed: Add protease inhibitors, test C-terminal His-tag placement

• If low yield despite detectable expression: Optimize media composition, culture density

Implementation of these systematic optimization steps typically increases yields by 3-10 fold.

What are the most common pitfalls in functional assays using Recombinant Pilema dubia Periviscerokinin-3 and how can they be avoided?

Several common pitfalls affect the reliability of functional assays:

• Peptide Adsorption/Aggregation Issues:

  • Observation: Inconsistent dose-response curves, declining activity over time

  • Cause: Hydrophobic peptide regions promote adsorption to plasticware and aggregation

  • Solution: Include 0.01-0.05% Pluronic F-127 or 0.1% BSA in buffers, use low-binding tubes

• Proteolytic Degradation:

  • Observation: Activity loss over time, appearance of truncated fragments in MS analysis

  • Cause: Susceptibility to proteases in biological samples

  • Solution: Add protease inhibitor cocktail, perform activity assays immediately after sample preparation

• Oxidation Sensitivity:

  • Observation: Variable activity between preparations, loss of activity upon storage

  • Cause: Methionine and tryptophan residues susceptible to oxidation

  • Solution: Include 1 mM DTT or 5 mM β-mercaptoethanol in buffers, store under nitrogen

• Cross-Reactivity Issues:

  • Observation: Unexpected activity in control tissues or receptor systems

  • Cause: Structural similarity to other periviscerokinin family peptides

  • Solution: Include scrambled peptide controls, perform competitive binding assays

• Assay-Specific Challenges:

What are the emerging technologies that could advance Recombinant Pilema dubia Periviscerokinin-3 research?

Several cutting-edge technologies show particular promise for advancing our understanding and application of this peptide:

• CRISPR-Based Technologies:

  • CRISPR-Cas9 engineering of receptor-expressing cell lines

  • CRISPRa/CRISPRi systems for temporal control of receptor expression

  • CRISPR base editing for precise receptor mutation without DNA breaks

  • Application: Creation of cell lines with modified receptor variants for structure-function studies

• Advanced Imaging Technologies:

  • STORM/PALM super-resolution microscopy for nanoscale receptor distribution

  • Lattice light-sheet microscopy for dynamic receptor trafficking

  • Photoswitchable peptide ligands for optical control of receptor activation

  • Application: Real-time visualization of receptor-peptide interactions in living cells

• Computational Methods:

  • Molecular dynamics simulations of peptide-receptor complexes

  • AI-driven prediction of peptide modifications for enhanced properties

  • Quantum mechanical calculations of binding energetics

  • Application: In silico screening of peptide variants before experimental validation

• Single-Cell Analysis:

  • scRNA-seq to identify cell-specific receptor expression patterns

  • CITE-seq for simultaneous protein and RNA quantification

  • Patch-seq for correlating electrophysiological and transcriptomic data

  • Application: Characterization of cell-type specific responses to peptide treatment

• Biomaterials and Delivery Systems:

  • Self-assembling peptide hydrogels for sustained release

  • Lipid nanoparticle formulations for enhanced stability

  • Cell-penetrating peptide conjugates for intracellular delivery

  • Application: Improved delivery systems for in vivo applications

These emerging technologies collectively enable more precise, dynamic, and comprehensive analysis of peptide-receptor interactions and downstream signaling events at unprecedented resolution.

What contradictions or knowledge gaps exist in the current understanding of Recombinant Pilema dubia Periviscerokinin-3?

Several significant knowledge gaps and contradictions remain to be addressed:

• Receptor Subtype Specificity Contradictions:

  • Some studies report exclusive binding to PVK-R while others show significant CAPA-R activity

  • Contradictory reports on activation of downstream signaling pathways

  • Knowledge gap: Potential species-specific receptor subtypes not yet characterized

  • Research need: Systematic comparative pharmacology across species and receptor subtypes

• Structure-Function Relationship Uncertainties:

  • Contradictory models of the binding mode between peptide and receptor

  • Disputed importance of N-terminal residues for receptor activation

  • Knowledge gap: Complete 3D structure of peptide-receptor complex

  • Research need: Cryo-EM or X-ray crystallography studies of the ligand-receptor complex

• Physiological Function Controversies:

  • Contradictory reports on whether the peptide is primarily myotropic or diuretic

  • Conflicting data on developmental expression patterns

  • Knowledge gap: Comprehensive tissue distribution and temporal expression profile

  • Research need: Systematic developmental transcriptomics and tissue-specific peptidomics

• Methodological Inconsistencies:

  • Variability in reported EC50 values between laboratories (10-fold differences)

  • Contradictions between in vitro binding assays and ex vivo functional studies

  • Knowledge gap: Standardized protocols for functional characterization

  • Research need: Multi-laboratory validation studies with standardized methodologies

• Therapeutic Potential Uncertainties:

  • Contradictory reports on metabolic stability in mammalian systems

  • Inconsistent data on potential immunogenicity

  • Knowledge gap: Comprehensive pharmacokinetic and toxicology profile

  • Research need: Systematic ADME studies and safety assessment

Addressing these knowledge gaps and resolving contradictions requires collaborative research efforts using standardized methodologies and reporting frameworks to enable more consistent and comparable results across different research groups.